Main > ONCOLOGY (**) > Multiple Myeloma*** > Treatment > Co: IN. R. DoxoRubicin Liposome+

---

Co: IN. R. DoxoRubicin Liposome+'s subsections
(*) USA Approval Date: 2017. 05.17
+Bortezomib
Company

Co: IN. R. DoxoRubicin Liposome+'s products
This section has no products